Pharmacogenomic-pharmacokinetic study of selective estrogen-receptor modulators with intra-patient dose escalation in breast cancer.

CONCLUSION: TOR might be a valid alternative to TAM in patients predicted to be poor TAM metabolizers. PMID: 30734152 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30734152?dopt=Abstract

Source: Breast Cancer - February 7, 2019 Category: Cancer & Oncology Authors: Ishiguro H, Ohno S, Yamamoto Y, Takao S, Sato N, Fujisawa T, Kadoya T, Kuroi K, Bando H, Teramura Y, Iwata H, Tanaka S, Toi M Tags: Breast Cancer Source Type: research